Investigational drug · Phase 2
SKB518
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Gynecological Malignancies, Lung Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: May 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "SKB518"
First trial start
2025
Aug 29, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SKB518", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Gynecological Malignancies
- Lung Carcinoma
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SKB518" as an intervention, largest first.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT07448922 · 280 participants (planned) · Start Apr 8, 2026 · Primary completion Dec 31, 2027
Drug: SKB518 for injection; Carboplatin (AUC 5) and 2 more · For: Advanced Gynecological Malignancies
Sites: Chongqing, China; Shanghai, China
- A Study of SKB518 in Patients With Lung CancerPivotal-lookingRecruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT07019675 · 192 participants (planned) · Start Aug 29, 2025 · Primary completion Feb 20, 2027
Drug: SKB518; Tislelizumab and 1 more · For: Lung Carcinoma
Sites: Shenzhen, China; Nanning, China; Zhengzhou, China · 17 sites in all
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT06428331 · 150 participants (planned) · Start Jul 4, 2024 · Primary completion Jun 30, 2026
Drug: SKB518 for injection · For: Advanced Solid Tumors
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Gynecological Malignancies
- BRY812Phase 21 trial
BioRay Pharmaceutical Co., Ltd. · Advanced Gynecological Malignancies
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.